These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37369494)

  • 41. Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase.
    Kaewmeesri P; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
    Asian Pac J Cancer Prev; 2021 Jan; 22(1):219-225. PubMed ID: 33507702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
    Ang C
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma.
    Raggi C; Fiaccadori K; Pastore M; Correnti M; Piombanti B; Forti E; Navari N; Abbadessa G; Hall T; Destro A; Di Tommaso L; Roncalli M; Meng F; Glaser S; Rovida E; Peraldo-Neia C; Olaizola P; Banales JM; Gerussi A; Elvevi A; Droz Dit Busset M; Bhoori S; Mazzaferro V; Alpini G; Marra F; Invernizzi P
    Am J Pathol; 2019 Oct; 189(10):2090-2101. PubMed ID: 31351075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
    Tessiri S; Techasen A; Kongpetch S; Namjan A; Loilome W; Chan-On W; Thanan R; Jusakul A
    PeerJ; 2022; 10():e12750. PubMed ID: 35070505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
    Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
    World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations.
    Varghese AM; Patel J; Janjigian YY; Meng F; Selcuklu SD; Iyer G; Houck-Loomis B; Harding JJ; O'Reilly EM; Abou-Alfa GK; Lowery MA; Berger MF
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myricetin ameliorates cytokine-induced migration and invasion of cholangiocarcinoma cells via suppression of STAT3 pathway.
    Tuponchai P; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
    J Cancer Res Ther; 2019; 15(1):157-163. PubMed ID: 30880773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
    Braun S; McSheehy P; Litherland K; McKernan P; Forster-Gross N; Bachmann F; El-Shemerly M; Dimova-Dobreva M; Polyakova I; Häckl M; Zhou P; Lane H; Kellenberger L; Engelhardt M
    Expert Opin Investig Drugs; 2021 Nov; 30(11):1071-1080. PubMed ID: 34698609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma.
    Poosekeaw P; Pairojkul C; Sripa B; Sa Ngiamwibool P; Iamsaard S; Sakonsinsiri C; Thanan R; Ungarreevittaya P
    PLoS One; 2021; 16(11):e0259075. PubMed ID: 34780466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FGFR2 Inhibition in Cholangiocarcinoma.
    Vogel A; Segatto O; Stenzinger A; Saborowski A
    Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA damage to bone marrow stromal cells by antileukemia drugs induces chemoresistance in acute myeloid leukemia via paracrine FGF10-FGFR2 signaling.
    Yu S; Ye J; Wang Y; Lu T; Liu Y; Liu N; Zhang J; Lu F; Ma D; Gale RP; Ji C
    J Biol Chem; 2023 Jan; 299(1):102787. PubMed ID: 36509141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
    Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion.
    Dana P; Saisomboon S; Kariya R; Okada S; Obchoei S; Sawanyawisuth K; Wongkham C; Pairojkul C; Wongkham S; Vaeteewoottacharn K
    Cell Oncol (Dordr); 2020 Apr; 43(2):211-222. PubMed ID: 31729681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements.
    Neuzillet C
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):773-775. PubMed ID: 34358483
    [No Abstract]   [Full Text] [Related]  

  • 56. Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways.
    Laphanuwat P; Kongpetch S; Senggunprai L; Prawan A; Kukongviriyapan V
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):115-123. PubMed ID: 35092379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures.
    Sridharan V; Neyaz A; Chogule A; Baiev I; Reyes S; Barr Fritcher EG; Lennerz JK; Sukov W; Kipp B; Ting DT; Deshpande V; Goyal L
    Clin Cancer Res; 2022 Dec; 28(24):5431-5439. PubMed ID: 36190545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
    Botrus G; Raman P; Oliver T; Bekaii-Saab T
    Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
    Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
    JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma.
    Lamarca A; Ostios L; McNamara MG; Garzon C; Gleeson JP; Edeline J; Herrero A; Hubner RA; Moreno V; Valle JW
    Cancer Treat Rev; 2023 Dec; 121():102627. PubMed ID: 37925878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.